New PET scan agent could predict cancer therapy success, but trial never started

NCT ID NCT06922825

Terminated Diagnosis Sponsor: Eben Rosenthal Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MRI or CT scans. However, the trial was withdrawn before any patients were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI-46 (a radioactive imaging agent)
What this could lead to: If it had succeeded, this could have pointed toward a more accurate imaging method to predict how well antibody therapy works in solid tumor patients.
What could go wrong: This trial was withdrawn before enrolling anyone, so no data was collected. Even if it had run, it was a very early pilot study with only 50 participants, so results would have been preliminary and uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER MALIGNANCY SOLID TUMOR CANCER SOLID TUMOR MALIGNANCY

Contacts and locations

Locations

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.